NASDAQ:FPRX Five Prime Therapeutics (FPRX) Stock Price, News & Analysis → The AI Defense Stock Set to Soar (From Behind the Markets) (Ad) Free FPRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$38.00▼$38.0050-Day Range$37.65▼$38.0052-Week Range$2.61▼$38.90VolumeN/AAverage Volume1.98 million shsMarket Capitalization$1.77 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Five Prime Therapeutics alerts: Email Address Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Five Prime Therapeutics Stock (NASDAQ:FPRX)Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.Read More Ad DTICBOE shift unlocks new weekend income strategyYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend. Check out this training for the full story! FPRX Stock News HeadlinesMarch 28, 2024 | seekingalpha.comCMMB Chemomab Therapeutics Ltd.October 15, 2023 | nbcnews.com33+ best October Prime Day deals you can still shop right nowMarch 28, 2024 | DTI (Ad)Buy Friday, Sell Monday, No Exceptions Every week traders grind it out Monday through Friday… But neglect trading Friday to Monday… Or… “over the weekend” As one professional trader explains, trading over the weekend is one of the most forgiving strategies you can use today. It allows him to sidestep a lot of the midweek volatility. Yet, gives him the opportunity to target some of the markets biggest stock moves. Just recently, he posted a trade on Nordstrom… The trade was published at 3pm on a Friday afternoon and by Monday morning the trade more than doubled.October 11, 2023 | benzinga.comNK Cell Therapy Pipeline, Clinical Trials Studies, Emerging Drugs, and FDA Approvals 2023 (Updated)October 3, 2023 | nypost.comThe Giants’ prime time TV demons are haunting them nowAugust 3, 2023 | forbes.comWhat Is The Prime Rate Today?July 23, 2023 | usatoday.comWant $5? Amazon Prime members can get $5 off a $50 Amazon eGift Card right nowJuly 5, 2023 | forbes.comPrime Therapeutics Hires New CEO To Lead Pharmacy Benefit Combination With MagellanRxMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…July 2, 2023 | usatoday.comGet ready for Amazon Prime Day 2023 with Prime membership discounts available nowMarch 30, 2023 | benzinga.comPrime Therapeutics announces Mostafa Kamal as presidentMarch 19, 2023 | finance.yahoo.comPrime Therapeutics and Magellan Rx to present seven managed care pharmacy research studies at AMCP conferenceMarch 1, 2023 | marketwatch.com2023-2029 Cystic Fibrosis (CF) Therapeutics Market Size and Porters Five Forces Analysis | Survey Report by Absolute ReportsOctober 27, 2022 | marketwatch.comMicrobiome Therapeutics Market 2022 Expected to Reach Significant Rate by 2025September 22, 2021 | feeds.bizjournals.comOral Covid vaccine developer nails down Peninsula spaceAugust 3, 2021 | nasdaq.comFive Prime Therapeutics, Inc. Common Stock (FPRX)See More Headlines Receive FPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Five Prime Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2020Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:FPRX CUSIPN/A CIK1175505 Webwww.fiveprime.com Phone415-365-5600FaxN/AEmployees87Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-137,200,000.00 Net Margins-554.71% Pretax MarginN/A Return on Equity-75.84% Return on Assets-49.08% Debt Debt-to-Equity RatioN/A Current Ratio5.35 Quick Ratio5.35 Sales & Book Value Annual Sales$14.87 million Price / Sales119.01 Cash FlowN/A Price / Cash FlowN/A Book Value$4.13 per share Price / Book9.20Miscellaneous Outstanding Shares46,572,000Free FloatN/AMarket Cap$1.77 billion OptionableOptionable Beta4.40 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Helen Louise Collins (Age 58)Exec. VP & Chief Medical Officer Comp: $637.25kMr. Francis W. Sarena (Age 50)Chief Strategy Officer & Sec. Comp: $646.49kMr. Thomas Civik (Age 52)Pres, CEO & Director Mr. David V. Smith M.B.A. (Age 61)Exec. VP & CFO Mr. David White (Age 57)Principal Accounting Officer Mr. Martin ForrestVP of Investor Relations & Corp. CommunicationsDr. Nallakkan S. ArvindanSr. VP of Strategic Technology OperationsMore ExecutivesKey CompetitorsSupernus PharmaceuticalsNASDAQ:SUPNAmneal PharmaceuticalsNASDAQ:AMRXGeronNASDAQ:GERNArdelyxNASDAQ:ARDXHarmony BiosciencesNASDAQ:HRMYView All Competitors FPRX Stock Analysis - Frequently Asked Questions How were Five Prime Therapeutics' earnings last quarter? Five Prime Therapeutics, Inc. (NASDAQ:FPRX) posted its quarterly earnings data on Friday, November, 6th. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.60) by $0.14. The biotechnology company earned $2.05 million during the quarter, compared to analyst estimates of $3.50 million. Five Prime Therapeutics had a negative trailing twelve-month return on equity of 75.84% and a negative net margin of 554.71%. Read the conference call transcript. What other stocks do shareholders of Five Prime Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Five Prime Therapeutics investors own include Pfizer (PFE), Nektar Therapeutics (NKTR), OPKO Health (OPK), TG Therapeutics (TGTX), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), ImmunoGen (IMGN), VBI Vaccines (VBIV) and Mallinckrodt (MNK). This page (NASDAQ:FPRX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe 3rd Revolution in WarfareWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsIs AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Five Prime Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.